Literature DB >> 23859655

New interfacial microtubule inhibitors of marine origin, PM050489/PM060184, with potent antitumor activity and a distinct mechanism.

Benet Pera1, Isabel Barasoain, Areti Pantazopoulou, Angeles Canales, Ruth Matesanz, Javier Rodriguez-Salarichs, Luis F García-Fernandez, Victoria Moneo, Jesús Jiménez-Barbero, Carlos M Galmarini, Carmen Cuevas, Miguel A Peñalva, J Fernando Díaz, José M Andreu.   

Abstract

We have investigated the target and mechanism of action of a new family of cytotoxic small molecules of marine origin. PM050489 and its dechlorinated analogue PM060184 inhibit the growth of relevant cancer cell lines at subnanomolar concentrations. We found that they are highly potent microtubule inhibitors that impair mitosis with a distinct molecular mechanism. They bind with nanomolar affinity to unassembled αβ-tubulin dimers, and PM050489 binding is inhibited by known Vinca domain ligands. NMR TR-NOESY data indicated that a hydroxyl-containing analogue, PM060327, binds in an extended conformation, and STD results define its binding epitopes. Distinctly from vinblastine, these ligands only weakly induce tubulin self-association, in a manner more reminiscent of isohomohalichondrin B than of eribulin. PM050489, possibly acting like a hinge at the association interface between tubulin heterodimers, reshapes Mg(2+)-induced 42 S tubulin double rings into smaller 19 S single rings made of 7 ± 1 αβ-tubulin dimers. PM060184-resistant mutants of Aspergillus nidulans map to β-tubulin Asn100, suggesting a new binding site different from that of vinblastine at the associating β-tubulin end. Inhibition of assembly dynamics by a few ligand molecules at the microtubule plus end would explain the antitumor activity of these compounds, of which PM060184 is undergoing clinical trials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23859655     DOI: 10.1021/cb400461j

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  16 in total

Review 1.  Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Authors:  Kinsie E Arnst; Souvik Banerjee; Hao Chen; Shanshan Deng; Dong-Jin Hwang; Wei Li; Duane D Miller
Journal:  Med Res Rev       Date:  2019-02-11       Impact factor: 12.944

2.  A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs.

Authors:  Andrea E Prota; Katja Bargsten; J Fernando Diaz; May Marsh; Carmen Cuevas; Marc Liniger; Christian Neuhaus; Jose M Andreu; Karl-Heinz Altmann; Michel O Steinmetz
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

3.  A previously undescribed tubulin binder.

Authors:  Jessica J Field; Andrew B Waight; Peter D Senter
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-03       Impact factor: 11.205

4.  First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.

Authors:  Elena Elez; Carlos Gomez-Roca; Arturo Soto Matos-Pita; Guillem Argiles; Thibaud Valentin; Cinthya Coronado; Jorge Iglesias; Teresa Macarulla; Sarah Betrian; Salvador Fudio; Katrin Zaragoza; Josep Tabernero; Jean-Pierre Delord
Journal:  Invest New Drugs       Date:  2018-11-09       Impact factor: 3.850

Review 5.  Enriching cancer pharmacology with drugs of marine origin.

Authors:  Paula C Jimenez; Diego V Wilke; Paola C Branco; Anelize Bauermeister; Paula Rezende-Teixeira; Susana P Gaudêncio; Leticia V Costa-Lotufo
Journal:  Br J Pharmacol       Date:  2019-12-23       Impact factor: 8.739

6.  Molecular basis of resistance to the microtubule-depolymerizing antitumor compound plocabulin.

Authors:  Areti Pantazopoulou; Carlos María Galmarini; Miguel A Peñalva
Journal:  Sci Rep       Date:  2018-06-05       Impact factor: 4.379

Review 7.  Highlights of marine natural products having parallel scaffolds found from marine-derived bacteria, sponges, and tunicates.

Authors:  Erin P McCauley; Ivett C Piña; Alyssa D Thompson; Kashif Bashir; Miriam Weinberg; Shannon L Kurz; Phillip Crews
Journal:  J Antibiot (Tokyo)       Date:  2020-06-08       Impact factor: 2.649

Review 8.  Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development.

Authors:  David J Newman; Gordon M Cragg
Journal:  Mar Drugs       Date:  2014-01-14       Impact factor: 5.118

9.  Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells.

Authors:  Carlos M Galmarini; Maud Martin; Benjamin Pierre Bouchet; María José Guillen-Navarro; Marta Martínez-Diez; Juan Fernando Martinez-Leal; Anna Akhmanova; Pablo Aviles
Journal:  BMC Cancer       Date:  2018-02-07       Impact factor: 4.430

Review 10.  Marine Sponge Natural Products with Anticancer Potential: An Updated Review.

Authors:  Cinzia Calcabrini; Elena Catanzaro; Anupam Bishayee; Eleonora Turrini; Carmela Fimognari
Journal:  Mar Drugs       Date:  2017-10-13       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.